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Abstract
Introduction: In lung fibrosis, alveolar epithelium degenerates progressively. The goal of regenerative medicine is
to aid repair and regeneration of the lost tissues in parenchyma and airways for which mobilization of tissue-
resident endogenous or bone marrow-derived exogenous stem cells niches is a critical step. We used a lung injury
model in mice to identify and characterize functional lung stem cells to clarify how stem cell niches counteract
this degenerative process.
Methods: Short term assay (STA) - Bleomycin-induced lung inflammation and fibrosis were assessed in a model of
idiopathic pulmonary fibrosis in wild-type (WT), gp91phox-/- (NOX-/-), and gp91phoxMMP-12 double knockout
(DKO) mice on C57Bl/6 background and Hoechst 33322 dye effluxing side population (SP) cells characterized. Long
term assay (LTA) - In a bleomycin induced lung fibrosis model in C57Bl6 mice, the number of mature cells were
quantified over 7, 14, and 21 days in bone marrow (BM), peripheral blood (PB), lung parenchyma (LP) and
brochoalveolar lavage (BAL) fluid by FACS. BrdU pulse chase experiment (10 weeks) was used to identify label
retaining cells (LRC). BrdU+ and BrdU- cells were characterized by hematopoietic (CD45+), pluripotency (TTF1+,
Oct3/4+, SSEA-3+, SSEA-4+, Sca1+, Lin-, CD34+, CD31+), and lung lineage-specific (SPC+, AQP-5+, CC-10+) markers.
Clonogenic potential of LRCs were measured by CFU-c assays.
Results: STA- In lung, cellularity increased by 5-fold in WT and 6-fold in NOX-/- by d7. Lung epithelial markers
were very low in expression in all SP flow sorted from lung of all three genotypes cultured ex vivo. (p < 0.01).
Post-bleomycin, the SP in NOX-/- lung increased by 3.6-fold over WT where it increased by 20-fold over
controls. Type I and II alveolar epithelial cells progressively diminished in all three genotypes by d21 post-
bleomycin. D7 post-bleomycin, CD45+ cells in BALf in NOX-/- was 1.7-fold > WT, 57% of which were Mf that
decreased by 67% in WT and 83% in NOX-/- by d21.LTA- Cellularity as a factor of time remained unchanged in
BM, PB, LP and BAL fluid. BrdU+ (LRC) were the putative stem cells. BrdU+CD45+ cells increased by 0.7-fold and
SPC+CC10+ bronchoalveolar stem cells (BASC), decreased by ~40-fold post-bleomycin. BrdU+VEGF+ cells
decreased by 1.8-fold while BrdU-VEGF+ cells increased 4.6-fold. Most BrdU- cells were CD45-. BrdU- BASCs
remained unchanged post-bleomycin. CFU-c of the flow-sorted BrdU+ cells remained similar in control and
bleomycin-treated lungs.
Conclusion: STA- Inflammation is a pre-requisite for fibrosis; SP cells, being the putative stem cells in the lungs,
were increased (either by self renewal or by recruitment from the exogenous bone marrow pool) post-bleomycin
in NOX-/- but not in DKO indicating the necessity of cross-talk between gp91phox and MMP-12 in this process; ex
vivo cultured SP progressively lose pluripotent markers, notably BASC (SPC+CC10+) - significance is unknown. LTA-
The increase in the hematopoietic progenitor pool in lung indicated that exogenous progenitors from circulation
contribute to lung regeneration. Most non-stem cells were non-hematopoietic in origin indicating that despite
tissue turnover, BASCs are drastically depleted possibly necessitating recruitment of progenitors from the
hematopoietic pool. Loss of VEGF+ LRC may indicate a signal for progenitor mobilization from niches. BrdU- BASC
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population may be a small quiescent population that remains as a reserve for more severe lung injury. Increase in
VEGF+ non-LRC may indicate a checkpoint to counterbalance the mobilization of VEGF+ cells from the stem cell
niche.
Introduction
Tissue injury and repair are ongoing processes in the
lung and result from acute and chronic exposure to
environmental insults. There are a myriad of effectors of
lung injury, including infectious agents, particulate and
chemical pollutants, radiation, and host defense
mechanisms gone awry. Many of these processes are
ablative in nature and require repair mechanisms that
regenerate mature lung tissue through cell proliferation
and differentiation.
Fundamental to understanding mechanisms of repair
are identifying and characterizing the cells that are
potentially capable of repopulating the injured tissue.
Currently, efforts are being made to identify 1) which
cell(s) repopulates regions of injured lung; 2) what their
source is (endogenous or resident cells vs. exogenous or
recruited cells) and 3) whether they are pluripotent
stem cells capable of self renewal or transient amplifying
cells that are multipoint but more lineage-committed. In
the lung, multiple cell populations contribute to lung
repair [1]. Most, like the basal cells of the tracheal
epithelium, alveolar type II cells, bone marrow-derived
stem cells, and residential stem cells that potentially
serve the vascular compartment appear to be anatomi-
cally localized [2,3]. Others, like the side population (SP)
cells, have not yet been localized to a single lung com-
partment. The molecular phenotype of hematopoietic
stem cells (HSC) has been extensively characterized and
is defined as a population of cells that are CD45+, Sca-1
+, c-kit+, and Lin-. HSC are further characterized by
their ability to rapidly efflux the DNA dye Hoechst
33342 [4,5].
The existence of putative lung tissue stem cells has
only been suggested relatively recently through the use
of rodent injury models in which abundant progenitor
cells are depleted through either chemical or physical
means [6-9]. At least three distinct regions have been
described that support populations of lung tissue stem
cells: intercartellagenous regions of tracheobronchial air-
ways [6], neuroepithelial bodies (NEB) in bronchioles
[8], and the bronchoalveolar duct junction (BADJ) [7,8].
Each region harbors putative tissue stem cells that share
the common properties of a relatively undifferentiated
phenotype, infrequent proliferation (demonstrated
through use of DNA label retention assays), and a differ-
entiation potential that is appropriate for the compart-
ment in which they reside. A combination of
immunophenotypic and cell ablative strategies has been
employed to demonstrate that bronchiolar stem cells
residing within both the NEB and BADJ microenviron-
ments represent a Clara cell secretory protein (CCSP)-
expressing variant Clara cell, and that the BADJ-asso-
ciated population is dual-positive for both CCSP and
pro-surfactant protein C. Recent studies by Kim and
colleagues suggest that CCSP/SP-C dual-positive cells
can be enriched based upon their unique cell surface
phenotype (Sca1+, CD34+, CD31-, CD45-) and main-
tained long-term in vitro [9]. The report by Summer et
al. [10] adds to our understanding of the lung SP and
its function by phenotypically characterizing these cells.
The authors have demonstrated that there are both
CD45+ and CD45- lung SP cells and that both of these
populations are contributed to by the bone marrow
compartment, as demonstrated by whole bone marrow
transplantation experiments.
Rationale for the long term assay
In a previous study, the gp91phox-/- mouse had a spon-
taneous pro-inflammatory phenotype and then a more
exaggerated emphysematous phenotype in a cigarette
smoke-induced mouse model, while a double knockout
(DKO) mouse lacking in both gp91phox and MMP12
failed to develop emphysema, even after chronic cigar-
ette smoke exposure for over a month. This model is
chiefly by macrophage-driven pathogenesis, while an
allergen-induced asthma model is Th2 cytokine-driven
and a lymphocyte-orchestrated model. The aim of the
study was to explore whether reactive oxygen species
and matrix proteases may have a role in an allergic set-
up where phagocytic cells are responsible for much of
the downstream regulation of the inflammatory process.
Further to the allergic injury model, which is mainly
inflammatory in nature, we wished to explore the status
of regeneration in the mouse lung and thus tease out
the lung stem cell niches to reveal themselves. Hence an
injury model of bleomycin-induced idiopathic pulmon-
ary fibrosis was used.
Rationale for the short term assay
Stem cells are known to efflux Hoechst dye very slowly,
and so when flow is sorted at 90 minutes post-Hoechst
incubation, the cells that efflux the dye are gated and
sorted as the SP cells that are assumed to be the lung
stem cells. Previously most SP studies were performed
on bone marrow-derived cells. To our knowledge, there
is no publication to date about sorting and ex vivo
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culture of SP cells from the lung. Ours is the first study
of this nature before and seven days after a single intra-
tracheal (i.t.) instillation of 0.075 U/ml bleomycin, the
lungs from C57Bl/6 mice of three genotypes, namely
wildtype (WT), gp91phox-/- (NOX-/-) and MMP12-
gp91phox DKO, were digested with dispase 1.2 U/ml in
37°C for an hour and then incubated with 1:200 from a
Hoechst stain. They were then aliquoted and frozen at
-20°C in a 37°C water bath for 90 minutes, and flow was
sorted on FACSAria gating in a small (0.1%) cell popula-
tion forming the characteristic ‘shoulder’ of actively dye-
effluxing cells. These cells were then plated in mouse
embryonic stem (ES) medium+ in straws in liquid nitro-
gen. The mice were grouped as WS mice (WT + saline)
and WB mice (WT + bleomycin) and were characterized
by surface marker expression through 5 days of culture
and then frozen.
The studies presented here were to approach a funda-
mental question in pulmonary pathophysiology; that is,
what are the mechanisms that dictate tissue repair after
both acute and chronic injury? This is a question that is
central to our understanding of how tissue repair takes
place under certain pathophysiological conditions and
not under others. We have used knockout mice that dif-
fer in their fibrotic response to bleomycin, to tease out
differences in cellular populations that may be responsi-
ble for the induction of tissue injury or repair in the
short (14 days) and long term (10 weeks).
Materials and methods
Mice
Both gp91phox-/- mice [11] (Jackson Laboratories, Bar
Harbor, ME, USA) and mmp12-/- mice were on a
C57Bl/6J background and had been outcrossed and then
intercrossed for three generations to generate animals
deficient in both genes. C57BL6 mice (Taconic) (WT)
were used as the control group. In total the following
number of animals used in each group were as follows:
(1) WT group-control (or with alum only), 14; ovalbu-
min (OVA)-treated, 16; (2) NOX-/- group-control, 14,
OVA-treated, 15; (3) MMP12NOX-/- group-control, 16;
OVA-treated, 14. Animals were maintained under strict
specific pathogen-free (SPF) conditions following guide-
lines set down by the University of Washington Institu-
tional Animal Care and Use Committee (IACUC) under
protocol numbers 21-6404 and 2437-05.
Mouse model of bleomycin-induced pulmonary fibrosis
A single i.t. dose of 0.075 U/ml of bleomycin in 40 μl
saline was administered (day 0), and mice were sacri-
ficed 14 and 21 days later. The C57Bl/6 mice were kept
under animal bio-safety level (ABSL)-2 conditions
approved by the IACUC of the University of Washing-
ton, and were monitored daily. They were housed under
SPF conditions and were given food and water ad libi-
tum. They were sacrificed on day 14. One week after
bleomycin administration, mice developed marked inter-
stitial and alveolar fibrosis, detected in lung sections by
Masson’s trichrome stain. Analysis of cell populations
by enzymatic digestion by collagenase type IV was fol-
lowed by cell counting in a Z1 Beckman Coulter particle
counter (Bechman Coulter Inc, CA, USA), and subsets
were identified and quantified by Flow Cytometry
(FCM), and total and differential count of hematoxylin
and eosin (H&E)-stained cytospin smears of single cell
suspensions show loss of type I and type II alveolar
epithelial cells and influx of macrophages. Alveolar
epithelial cells types I and II (AEI and II) were isolated
following standard protocol.
Bromodeoxyuridine pulse chase
Bromodeoxyuridine (BrdU) is a DNA analogue. Slow
cycling cells are assumed to be stem cells and pulsing of
control vs. bleomycin-treated, with a single i.t. dose of
0.075 U/ml bleomycin given to WT C57Bl/6 mice at 12
hr intervals over two, four and six days intraperitoneal
(IP), and pulse chase over ten weeks was expected to
yield BrdU+ and BrdU- cells. While negative cells are
assumed to be mature regularly cycling cells, BrdU+
cells after ten weeks of chase are most likely label-
retaining cells (LRC), that is, slow cycling stem cells that
start cycling late and hence retain the label for longer.
C57Bl/6 mice were given the i.t. instillation of bleomy-
cin under brief isofluorane anesthesia, and animals were
maintained under SPF conditions in the University of
Washington (UW) animal facilities and sacrificed peri-
odically to assess the above.
Institutional approval
All animal experimentation methodology was approved
by the University of Washington IACUC, protocol num-
bers 21-6404 (WRH) and 2437-05 (TP).
Bronchoalveolar lavage
After pulmonary function testing, mice underwent
exsanguination by intra-orbital arterial bleeding and
then bronchoalveolar lavage (BAL) (0.4 ml three times)
of both lungs. Total BAL fluid cells were counted from
a 50 μl aliquot and the remaining fluid was centifuged
at 200 g for 10 minutes at 4°C, and the supernatants
were stored at -70°C for assay of BAL cytokines later.
The cell pellets were re-suspended in FCS and smears
were made on glass slides. After air drying, the cells
were stained with Wright-Giemsa (Biochemical Sciences
Inc., Swedesboro, NJ, USA) and their differential count
was taken under a light microscope at 40 × magnifica-
tion. Cell number refers to that obtained from lavage of
both lungs in each mouse.
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Lung parenchyma
Lung mincing and digestion was performed after lavage
as described previously [11] with 100 u/ml collagenase
for 1 hr at 37°C, and filtered through a 60# sieve
(Sigma, Aldrish Co, St Louis, MO, USA). All numbers
presented in this paper refer to cells obtained from one
lung/mouse. The cells recovered were primarily from
the lung parenchyma (LP), as the lungs were thoroughly
exsanguinated after ligating the vena cava to stop drai-
nage into the pulmonary circulation, prior to lavage and
enzymatic separation of parenchyma cells.
Lung histology
Lungs of other animals of the same group were fixed
overnight at 4°C in 4% paraformaldehyde. The tissues
were embedded in paraffin and cut into 5 μm sections.
A minimum of 15 fields was examined by light micro-
scopy. The intensity of cellular infiltration around pul-
monary blood vessels was assessed by H&E staining.
Airway mucus was identified by staining with alcian
blue and periodic acid Schiff staining as described pre-
viously [12].
Fluorescin-activated cell sorter (FACS) analysis
Cells from hemolysed peripheral blood (PB), bone mar-
row (BM), BAL, LP, spleen, mesenteric lymph nodes
(MLN), cervical lymph nodes (CLN), axillary lymph
nodes (LNX) and inguinal lymph nodes (LNI) were ana-
lyzed on a FACSCalibur (BD Immunocytometry Sys-
tems, San Jose, CA, USA) using the CELLQuest
program. Staining was performed using antibodies con-
jugated to fluorescin isothiocyanate (FITC), phycoery-
thrin (PE), allophucocyanin (APC), peridinin chlorophyll
protein (Per CP-Cy5.5) and Cy-chrome (PE-Cy5 and
PE-Cy7). The following BD Pharmingen (San Diego,
CA, USA) antibodies were used for cell surface staining:
APC-conjugated CD45 (30F-11); FITC-conjugated CD3
(145-2C11); PE-Cy5-conjugated CD4 (RM4-5);PE-conju-
gated CD45RC (DNL-1.9); APC-conjugated CD8 (53-
6.7); PE-Cy5 conjugated B220 (RA3-6B2); FITC-conju-
gated immunoglobulin (IgM); PE-conjugated CD19
(ID3); PE-conjugated CD21 (7G6); FITC-conjugated
CD23 (B3B4); APC-conjugated GR-1 (RB6-8C5) and PE-
conjugated Mac1 (M1/70). PE-Cy5 conjugated F4/80
(Cl:A3-1(F4/80)) was obtained from Serotec Ltd.,
Oxford, UK. PE-conjugated anti-a4 integrin (PS2) and
anti-vascular cell adhesion molecule (VCAM)-1(M/K-2)
were obtained from Southern Biotechnology, Birming-
ham, AL, USA. Irrelevant isotype-matched antibodies
were used as controls. For the non-hematopoietic cells
of the lung, the following markers were from Santa
Cruz, CA, USA, were used as unlabelled primary antibo-
dies: surfactant protein (SP)-C; Oct-3/4; stage-specific
embryonic antigens (SSEA)-3 and 4; thyroid
transcription factor (TTF)-1; aquaporin (AQP)-1 and
AQP-5. An FITC-labeled secondary antibody was used
for FACs detection. Thus, all the FACS surface marker
expression experiments were single marker analysis, not
combinatorial. We took 106 cells per sample in 50 ml
cell suspension in ice-cold PBS (16) and 105 events were
recorded per sort [13]. To eliminate differences in the
expression of activation markers by the choice of
enzymes used for isolation, a comparative was done
with collagenase, trypsin and dispase. Of these, dispase
was found to be the least modulating of marker expres-
sion, and digestion by this resulted in higher BrdU- cells
and less SP, showing that somehow cells were effluxing
dyes at a higher rate when digested thus. At this stage
we can only speculate as to the effect of these enzymes
on marker expression [14].
CFU-c assay
To quantify committed progenitors of all lineages, col-
ony-forming unit in culture (CFU-C) assays were per-
formed using methylcellulose semisolid media
(Stemgenix, Amherst, NY, USA) supplemented with an
additional 50 ng of stem cell factor (Peprotech, Rocky
Hill, NJ, USA) per ml. Next, 50,000 cells from BM,
500,000 cells from spleen, 0.01 million cells from lung
and BAL fluid (BALf), and 10 μl PB were plated on
duplicate 35-mm culture dishes and then incubated at
37°C in a 5% CO2-95% air mixture in a humidified
chamber for seven days. Colonies generated by that time
were counted using a dissecting microscope, and all col-
ony types (that is, burst-forming units-erythroid (BFU-
e), CFU-granulocyte-macrophage (CFU-GM), and CFU-
mixed (CFU-GEMM)) were pooled and reported as total
CFU-C. Total CFU-c per organ was calculated by extra-
polating CFU-c against number of plated cells to the
total number of cells in the organ.
Statistical analysis
Statistical differences among samples were tested by
Student t- test. A P value less than 0.05 was considered
statistically significant.
Results
Bleomycin-induced idiopathic pulmonary fibrosis model
C57Bl/6 female mice (eight to ten weeks of age),
instilled with bleomycin, were maintained under SPF
conditions in the UW animal facilities and sacrificed
periodically to the parameters shown in Figure 1. Lung
fibrosis, ancillary inflammatory parameters and inflam-
matory cell recruitment patterns were studied.
Assessment of extent of fibrotic and inflammatory damage
in the lung post bleomycin treatment
Mice were sacrificed at 10 weeks and blood, LP enzyma-
tically digested by dispase 1.2 U/ml and BALf (lavage
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volume 400 μl × 3 with ice cold PBS) were analyzed.
The total number of cells was assessed by the Coulter
particle counter. PB was extrapolated to 2 ml (equal to
the volume of total PB in a 20 gm mouse), LP of both
lungs and BALf were also analyzed for both lungs in
each mouse (Figure 2).
Total freshly synthesized tropocollagen quantified in
the post-bleomycin lung of WT and gp91phox-/- mice
show respectively a 3-fold and 4.6-fold increase com-
pared to their untreated or placebo-treated counterparts.
DKO mice strikingly showed no increase in collagen
content and lung homogenate showed tropocollagen at
similar levels to that of untreated mice (Figure 2). By
histology and histochemical and immunohistochemical
staining, LP and areas surrounding small bronchoalveo-
lar ducts show enhanced inflammatory recruitment,
increased transforming growth factor (TGF)-b secretion,
and collagen deposits around small and large airways
(Figure 3).
Inflammatory cell accumulation in the lungs and airways
over time post-bleomycin treatment
Table 1 shows significant inflammation in the lungs and
airways by day 7 after bleomycin treatment. While WT
mice had a 7-fold increase in total inflammatory cell
number in the BALf compared to untreated WT mice
post-bleomycin, gp91phox-/- had more than 10-fold
Bleomycin 
i.t. 
Cellularity in BM, PB, LP and BALf, collagen content of lung, histology of 
lung for airway remodelling by Masson’s Trichrome stain and picro sirius 
red stain, TGF  immunohistochemistry in lungs 
0 7 14 21 
Days of treatment 
Figure 1 Study design to generate fibrosis in mouse lung. C57Bl/6 female mice (8 to 10 weeks of age) were intra-tracheally instilled with
0.075 U/ml bleomycin in 40 ml volume under brief isofluorane anesthesia, and animals were maintained under SPF conditions in the University
of Washington animal facilities, and sacrificed periodically to assess the above. Abbreviations: i.p., intra-peritoneal; i.t., intra-tracheal; BALf,
























Figure 2 Increase in collagen content of lung post-bleomycin in gp91phox-/- but not in MM12-gp91phox double knockout mice. Total
collagen content freshly synthesized in lung was measured by Sircol assay. Data represent mean of 2 independent experiments, n = 4/group.
Data are expressed as avergae ± SEM. *P < 0.05 compared to the post-OVA value in wildtype mice. Abbreviations: WS, saline-treated wildtype
(baseline); WB, bleomycin-treated (single intra-tracheal dose of 0.075 U/ml bleomycin and animals were sacrificed 14 and 21 d later. Here day 21
data are shown); NOXS, saline-treated gp91phox null; NOXB, bleomycin-treated gp91phox null; DKOS, saline treated MMP12- gp91phox double
knockout; DKOB, bleomycin-treated MMP12- gp91phox double knockout.
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increase, but DKO had no appreciable inflammation in
the untreated or treated lung. Inflammatory cell compo-
nents in the airways of bleomycin-treated lungs in WT
mice were mostly lymphocytes (157-fold increase) and
neutrophils (150-fold increase) while macrophages
increased 2.6-fold. In the gp91phox-/- mice, however,
there was a slight shift in the inflammatory cell recruit-
ment profile, while in the post-bleomycin lung, lympho-
cytes (187-fold increase) occupied a higher share of the
inflammatory exudates in proportion to the other cell
types, which shows apportionment of a 6-fold higher
number of macrophages, and a 35-fold increase in the
number of neutrophils compared to the control. There-
fore, in the gp91phox-/- lung the shift is in the myeloid
population, which showed a somewhat diminished
migration to airways compared to the lymphoid popula-
tion, although overall inflammation was more pro-
nounced than in the WT mice. In DKO mice, the
airways contained a slightly higher number of inflamma-
tory cells post-bleomycin, but the number was similar to
the WT control and was not significantly enhanced.
Stem cell niches characterization in the bleomycin-
induced injury model
Long term BrdU pulse chase assay
A long-term assay was performed to detect stem cell
niches exposed by the bleomycin-induced injury model




A. B. C. 
Figure 3 Increased inflammation and fibrosis in lung of WT and gp91phox-/- mice but not MMP12gp91phox double knockout mice.
At 21d post-bleomycin treatment, mice were sacrificed and lungs were fixed overnight in 4% paraformaldehyde and embedded in paraffin.
Sections of 8 m were dye-stained by A, Masson’s Trichrome stain and C, Picro Sirius red and were immunostained with TGFb antibody and color
developed by Diaminobenzidine (DAB). (B). Arrows indicate blue collagen deposits (A), TGFb positive stain (B) and red collagen staining (C). In A,
pink-purple stains indicate cytoplasm, and blue the nuclei of inflammatory cells. Light blue stains are collagenous deposits. While wildtype and
gp91phox-/- (designated as NOX-/-) show increased collagen deposits and inflammation around airways post-ovalbumin (all sections are those
of post- ovalbumin lung), the MMP-12-gp91phox double knockout lung shows minimum collagen deposition as well as TGFb expression. While
A and B were at 60 × magnification, C was at 10 × magnification. A inset shows another area of collagen deposition in bleomycin-treated
wildtype; NOXB and DKOB were bleomycin-treated gp01 phox-/- and double knockout mice respectively. The photomicrographs were taken
using an Olympus VX4L microscope and Nikon digital camera. All photomicrographs were at 60 × magnification. Abbreviations: WB, wildtype
mice treated with bleomycin; NOXB, bleomycin-treated gp91phox null; DKOB, bleomycin-treated MMP12- gp91phox double knockout.
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Table 1 Number of hematopoietic and non-hematopoietic cells in BALf and lung a week after bleomycin treatment - trends in cellular migration to BALf and
lung post-bleomycin over time
A. Number of cells in BALF after a week of bleomycin treatment
WT saline (day 7) WT bleomycin (day 7) NOX saline (d7) NOX bleomycin (day 7) DKO saline (day 7) DKO bleomycin (day 7)
Total cell count (×105/ml) 4.27 ± 0.184 28.3 ± 0.224 4.515 ± 0.223 48.91* ± 1.59 2.61 ± 0.16 8.42 ± 0.13




































B. Number of CD45+ cells in BALf before and after Bleomycin treatment
BALf
105/ml WS WB7 WB14 WB21 NOXS NOXB21 DKOS DKOB21
Total cells 4.27 ± 0.18 28.3 ± 0.22 10.32 ± 2.74 9.32 ± 1.74 4.51 ± 0.23 8.36 ± 1.32 4.55 ± 0.16 5.03 ± 1.94
Macrophage 4.16 ± 0.57 11.14 ± 4.08 8.91 ± 4.93 7.06 ± 3.92 3.86 ± 1.07 6.91 ± 1.96 3.91 ± 0.74 4.03 ± 0.43
Lymphocyte 0.08 ± 0.01 12.63 ± 2.49 1.76 ± 0.67 1.33 ± 0.67 1.32 ± 0.54 2.43 ± 0.43 1.44 ± 0.32 0.56 ± 0.21
PMN 0.03 ± 0.01 4.5 ± 0.97 0.41 ± 0.07 0.87 ± 0.32 0.67 ± 0.32 1.02 ± 0.22 0.67 ± 0.11 0.41 ± 0.13
C. Number of (CD45+) cells in lung parenchyma before and after bleomycin treatment
LP (d7)
105/m1 WS WB NOXS NOXB DKOS DKOB
Total cells 7.27 ± 0.07 38.3 ± 4.04 8.86 ± 0.08 54.19* ± 2.6 6.85 ± 0.27 9.56 ± 0.65
Macrophage 6.16 ± 0.57 22.14 ± 4.08 7.13 ± 2.43 31.38* ± 11.32 5.41 ± 1.43 6.36 ± 2.71
Lymphocyte 1.08 ± 0.01 9.63 ± 2.49 0.97 ± 0.12 21.41* ± 4.93 0.93 ± 0.21 2.47 ± 0.67
PMN 0.03 ± 0.01 7.5 ± 0.97 0.72 ± 0.04 1.34 ± 0.15 0.51 ± 0.03 0.73 ± 0.33
% WS WB NOXS NOXB DKOS DKOB
Macrophage 84.73 ± 1.86 57.80 ± 11.75 80.47 ± 12.96 57.96 ± 2.98 78.97 ± 3.76 66.52 ± 5.98
Lymphocyte 14.85 ± 2.84 25.14 ± 4.96 10.94 ± 1.95 39.50 ± 3.67 13.57 ± 3.98 25.83 ± 8.43
PMN 0.41 ± 0.04 19.58 ± 6.73 8.12 ± 2.07 2.47 ± 1.09 7.44 ± 1.97 7.63 ± 2.06
D. Number of CD45- cells in lunb parenchyma counterstained with alveolar epithelial cell markers before and after bleomycin treatment
saline bleomycin
WT Day 21 Day 7 Day 14 Day 21
AEI 95.7 ± 4.87 79.47 ± 2.86 67.43 ± 1.76 58.41 ± 4.83
AEII 4.3 ± 1.76 9.41 ± 1.86 8.66 ± 1.07 5.96 ± 1.12
NOX-/-
AEI 95.7 ± 3.87 66.21 ± 58.23 ± 2.34 56.14 ± 3.97

















Table 1 Number of hematopoietic and non-hematopoietic cells in BALf and lung a week after bleomycin treatment - trends in cellular migration to BALf and
lung post-bleomycin over time (Continued)
DKO
AEI 95.7 ± 4.16 96.23 ± 4.75 96.44 ± 11.23 97.41 ± 3.87
AEII 4.3 ± 0.56 4.5 ± 0.09 4.86 ± 1.94 4.96 ± 1.87
A. Number of cells in BALf after a week of bleomycin treatment. B. Number of CD45+ cells in BALf before and on days 7, 14 and 21 after bleomycin treatment (one intratracheal dose of 0.074 U/ml in 40 ml volume).
C. Number of (CD45+) cells in lung parenchyma (LP) before and after bleomycin treatment. D. Number of CD45- cells in LP counterstained with alveolar epithelial cell markers before and after bleomycin treatment.
After the single intra-tracheal dose of bleomycin, animals were sacrificed on days 7, 14 and 21 for the WT after bleomycin, and at days 7 and 21 only for the NOX-/- and DKO mice and WS. Cell number was
quantitated by hemocytometer and corroborated by Z1 particle counter (Beckman Coulter). Number of cells represent data from 2 independent experiments ± SEM. n = 4/group. Cell subsets were quantified by FACS
and morphologic differentiation under light microscope. Olympus BX41 at 40 × magnification. CD45+ cells were gated and macrophages (Gr1-F4/80hi), lymphocytes (CD3+ and B220+), and neutrophils (Gr-1hi F4/80-)
were identified, their percentages analyzed by CellQuestPro and their total numbers calculated from the total number of cells obtained by lavage as described in materials and methods. Data presented were pooled
from 2 independent experiments ± SEM. *P < 0.05 compared to WT post-bleomycin on corresponding time points). Abbreviations: WT (wild type), BALf, bronchoalveolar lavage fluid; NOX-/- (gp91phox knockout),
gp91phox MMp12 double knockout (DKO); WS, WT + saline (day 7); WB7, WT + post-bleomycin day 7; WB14, WT + post-bleomycin day 14; WB21, WT + post-bleomycin day 21; NOXS, gp91phox-/- + saline day 21;
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BrdU i.p. bid Cellularity BM, PB, LP, and BALf 
CFU assay of BrdU+ cells sorted from lung parenchyma 
BrdUpos and neg cells identified by FACS 
Figure 4 Study design of BrdU pulse chase of control and bleomycin-induced lung fibrosis model in mice. C57Bl/6 mice had
intratracheal instillation of 0.075 U/ml bleomycin in 40 ml volume under brief isofluorane anesthesia and animals were maintained under SPF
conditions in the University of Washington animal facilities, and sacrificed periodically to assess the above. Slow cycling cells are assumed to be
stem cells and pulsing of control vs. bleomycin-treated wildtype C57Bl/6 mice over two, four and six days i.p. at 12-hr intervals and pulse chase
over 10 weeks, was expected to yield BrdU+ cells and BrdU- cells. While negative cells are assumed to be mature regularly cycling cells, BrdU+
cells after 10 weeks of chase are most likely label retaining cells (slow cycling stem cells) that started cycling late and hence retain the label for
longer. BrdU is a DNA analogue. Abbreviations: i.p. intra-peritoneal; i.t. intra-tracheal; BALf, bronchoalveolar lavage fluid; BM, bone marrow; PB,
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Pulse days (2 i.p a day) 
BALf/2 lungs BrdU pulse chase cellularity 
Control 
Bleo 
Figure 5 Cellularity in bone marrow, peripheral blood, lung parenchma and bronchoalveolar lavage fluid before and after bleomycin
after 10 weeks of bromodeoxyuridine pulse chase. Total cell number in bone marrow, blood, lung and airways after 10 weeks of chase
following12-hourly pulsing for up to 6 days in the saline-treated control mice (Con) and bleomycin-treated (Bleomycin) (one i.t. dose of 0.075 U/
ml). P values < 0.05 compared to the control were considered significant. Data were averaged from three independent experiments. FACsans
and flow sorts were done in triplicate per sample. Samples were counted in duplicate tubes per sample for each data point (n = four to five per
group). Mortality was less than 2%. In this experiment no significant change was found in total cellularity. Abbreviations: BM, bone marrow; PB,
peripheral blood; BALf, bronchoalveolar lavage fluid; LP, lung parenchyma; BrdU, bromodeoxyuridine.
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5). Marker expression analysis by FACS was used to
help identify BrdU+ cells (possibly stem cells) and BrdU-
(either accessory cells characterized by their typical sur-
face marker expression or parenchyma other than stem
cells) were assessed as percent total cells by FCM by
conjugated monoclonal antibodies (Table 2). The total
number of cells remained unaltered in BM, PB, lung
and BALf. Probably after 10 weeks of chase, whatever
temporary alteration in cells had occurred in the short
term (one to three weeks post-bleomycin), reached equi-
librium at the end of ten weeks. BrdU+ cells are the
stem cells, and are identified by the marker expression
on them, thus, double-positive cells are stem cells and
are characterized by their marker expression. BrdU- cells
are the remaining cells that are also characterized by
their marker expression. These are presumably the non-
stem cells that may be accessory cells if present adjacent
to the stem cell niches (to be corroborated by Immuno-
histochemistry (IHC) by spatial distribution. The per-
centages shown in the datasheet were obtained by
gating on BrdU+ or BrdU- cells.
Detection of stem cells by CFU-C
BrdU single+ cells in the lung parenchyma were
decreased 4.8-fold post-bleomycin. Putative stem cell
populations seemed to be gradually depleted from the
lung upon bleomycin treatment. We plated 0.1 × 106
cells in semi-solid methyl cellulose and performed CFU-
counts after 14 days (Figure 6). BrdU+ cells from mouse
lungs collected from bleomycin-treated mice on day 2,
day 4 and day 6 of the pulse chase were statistically sig-
nificantly increased.
Detection of stem cells by marker expression
Characterization of BrdU+ cells
Only BrdU+ cells were sorted and plated, as these are
the slow cycling stem cells derived from the lung. Mar-
ker expression was studied by FACS analysis to charac-
terize stem and mature differentiated cells (Table 2).
TTF-1, which is a typical expression marker of AEII,
has been implicated in early lung development. Post-
bleomycin, there was a 4.9-fold decrease in these cells,
showing that putative progenitors are destroyed. Oct3/4
is an early pluripotent marker. Post-bleomycin there was
a one-fold decrease in the percent Oct3/4+ cells among
BrdU+ cells. This may indicate a universal downregula-
tion of pluripotency post-bleomycin and may be due to
an overall depletion of the stem cell reserve, or indivi-
dual cells may lose Oct3/4 expression in limited pockets
(calculation of the kd value by Scatchard analysis may
give a more exhaustive quantitative assessment).
Post-bleomycin, SSEA-3 and 4 were decreased 5.9-
and 6.14-fold, respectively, compared to the control.
Since these are stem cell-specific antigens, this may
again point towards an overall depletion of pluripotent
reserve cells in niches. Sca-1+ cells are mouse-specific
stem cells. Being BrdU+, these were undoubtedly stem
cells in the lung. A 22.6-fold decrease in Sca-1-BrdU
double+ cells may also indicate that the post-bleomycin
progenitor population decreased in the lung. Lineage-
negative cells are those that are non-hematopoietic in
origin and here, being BrDU+, are the definitively non-
hematopoietic cells in lung that have stem-like proper-
ties. A 2.6-fold decrease in these cells in bleomycin-trea-
ted mouse lungs indicates that stem cells of non-
hematopoietic origin were depleted. CD34+ cells are
hematopoietic cells and being BrdU+, must also have
stem-like properties. A 2.2-fold increase in these cells
post-bleomycin indicates that hematopoietic stem cells
definitely had an impact post-bleomycin on lung stem
cell content. Our theory is that either hematopoietic
stem cells from bone marrow or other tissues may travel
to injured lung to replenish the depleted lung stem cell
niche.
CD31+ cells are endothelial progenitors. There was a
1.9-fold increase in these cells, which are also BrdU+.
SP-C+ cells are AEII cells. There was a 14.3-fold
decrease post-bleomycin. AEII are established progeni-
tors that are assumed to trans-differentiate to AEI upon
bleomycin-induced depletion of the former. Being BrdU
+ here, they are conclusively slow cycling cells, although
expressing SP-C, a marker of mature AEII cells. This is
interesting because decrease in this double-positive
population shows either that pre-destined SP-C+ LRC
are depleted post-bleomycin or that SP-C+ cells, which
revoke their progenitor property and become slow
cycling, probably as a preamble to trans-differentiation
into AEI, become increasingly depleted. The percentage
of AQP-5+ AEI cells was quite low to start with and
became lower post-bleomycin. However, as a technical
note, since the percentage of positive cells was extre-
mely low to start with (control), the 6-fold decrease
post-bleomycin may not be significant.
Some Clara cells have also been traditionally known to
possess stem-like properties (for instance, naphthalene
resistance). Here CC-10+ BrdU+ cells increased by 1.2-
fold post-bleomycin, showing that Clara cells probably
have some definite responsive function to a bleomycin
challenge.
Characterization of non-stem cells (BrdU-)
These are the normally cycling cells, presumably the
other cells constituting the rest of the LP. There was no
significant difference between the pre- and post-bleomy-
cin BrdU- populations in the mouse lung. BrdU+ and
BrdU- cells showed the expected relative distribution in
the same scattergram making 100%. TTF-1+ BrdU- cells
were decreased 36.78-fold. Since TTF-1 is co-expressed
on AEII, increase in this cell population may indicate an
alteration in AEII response to bleomycin. Whether this
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Table 2 Percent positive cells by FACS within BrdU+ and BrdU- populations in lung for pluripotent and pulmonary lineage-specific markers
A. Percent positive cells by FACS within BrdU+ population in lung
BrdU+ TTF-1+ Oct3/4+ SSEA-3+ SSEA-4+ Sca-1+ Lin- CD34+ CD31+
Con 2d 8.51 ± 0.23 20.55 ± 0.30 86.18 ± 1.05 40.9 ± 0.83 48.85 ± 0.25 932 ± 1.70 95.54 ± 0.78 1.08 ± 0.02 2.39 ± 0.10
Con 6d 9.05 ± 0.03 21.11 ± 0.59 85.67 ± 0.93 42.90 ± 1.11 46.44 ± 2.24 87.66 ± 2.56 92.30 ± 0.66 1.58 ± 0.20 1.92 ± 0.63
Bleo 2d 2.67 ± 0.12 4.16 ± 0.12 78.25 ± 2.01 8.91 ± 0.02 8.97 ± 0.025 3.67 ± 0.09 44.82 ± 1.75 2.42 ± 0.17 4.77 ± 0.18
Bleo 4d 1.83 ± 0.21 4.52 ± 0.45 80.58 ± 0.12 8.07 ± 0.15 8.57 ± 0.41 3.71 ± 0.30 38.05 ± 1.54 3.01 ± 0.49 4.60 ± 0.19
Bleo 6d 1.87 ± 0.07 4.37 ± 0.29 79.62 ± 0.74 8.12 ± 0.53 7.95 ± 0.043 4.46 ± 0.24 36.28 ± 1.79 3.32 ± 0.40 3.60 ± 0.26
SP-C+ AQP-5 CC-10 CD45+ CD45- SP-C+
CC10+
VEGF+
Con 2d 4.69 ± 0.13 0.83 ± 0.02 2.52 ± 0.15 2.13 ± 0.02 96.93 ± 0.90 82.80 ± 1.53 15.67 ± 0.86
Con 6d 4.59 ± 0.26 0.8 ± 0.004 2.42 ± 0.24 2.53 ± 0.23 93.95 ± 2.34 81.08 ± 0.42 13.78 ± 0.42
Bleo 2d 0.23 ± 0.05 0.14 ± 0.01 2.67 ± 0.09 3.42 ± 0.12 91.79 ± 1.60 2.43 ± 0.08 8.59 ± 0.29
Bleo 4d 0.54 ± 0.08 0.14 ± 0.02 3.16 ± 0.05 3.5 ± 0.20 90.38 ± 0.77 2.4 ± 0.56 8.70 ± 0.28
Bleo 6d 0.32 ± 0.04 0.14 ± 0.009 3.29 ± 0.12 3.57 ± 0.21 87.25 ± 2.29 2.08 ± 0.18 7.78 ±















Con 2d 92.13 ± 0.84 0.38 ± 0.10 0.560 ± 0.09 0.55 ± 0.02 0.47 ± 0.14 0.22 ± 0.15 0.2 ± 0.01 0.31 ± 0.06 0.03 ± 0.01
Con 6d 92.95 ± 0.71 0.31 ± 0.07 0.35 ± 0.02 0.4 ± 0.07 0.32 ± 0.03 0.06 ± 0.02 0.19 ± 0.04 0.22 ± 0.009 0.22 ± 0.09
Bleo 2d 89.06 ± 0.66 11.36 ± 0.59 1.11 ± 0.09 0.28 ± 0.07 0.35 ± 0.02 0.12 ± 0.07 0.34 ± 0.03 3.45 ± 0.09 0.71 ± 0.042
Bleo 4d 89.43 ± 0.66 12.13 ± 0. 74 1.34 ± 0.09 0.32 ± 0.04 0.26 ± 0.08 0.25 ± 0.03 0.24 ± 0.08 3.42 ± 0.23 0.8 ± 0.09
Bleo 6d 97.40 ± 1.1 11.68 ± 0.6 1.742 ± 0.16 0.31 ± 0.04 0.32 ± 0.01 0.16 ± 0.05 0.54 ± 0.05 2.90 ± 0.06 0.6 ± 0.086
SP-C+ AQP-5+ CC-10 CD45+ CD45- SP-C+
CC10+
VEGF+
Con 2d 5.59 ± 0.11 90.92 ± 0.50 1.30 ± 0.18 2.37 ± 0.17 80.38 ± 1.36 0.03 ± 0.01 2.86 ± 0.09
Con 6d 4.90 ± 0.14 85.75 ± 2.21 1.33 ± 0.21 2.7 ± 0.16 83.70 ± 1.66 0.12 ± 0.03 2.31 ± 0.14
Bleo 2d 1.48 ± 0.17 9.29 ± 0.41 2.60 ± 0.16 0.78 ± 0.06 76.15 ± 1.69 0.01 ± 0.004 12.74 ± 0.59
Bleo 4d 1.74 ± 0.03 217.49 ± 208.5 2.85 ± 0.08 0.65 ± 0.13 74.65 ± 1.37 0.02 ± 0.004 12.45 ± 0.84
Bleo 6d 1.52 ± 0.06 9.05 ± 0.18 2.36 ± 0.19 0.81 ± 0.13 74.05 ± 1.65 0.12 ± 0.06 10.65 ± 0.26
Bromodeoxyuridine-positive (BrdU+) cells were gated and inside (positive, and outside of the gate, BrdU-negative) cells were characterized by FACS with fluorochrome conjugated monoclonal antibodies markers of
pluripotence (TTF-1, SSEA-3,4, Oct ¾, SCA-1, lineage negative) and CD31 (endothelial progenitor) and CD34 (hematopoietic progenitor). Lung lineages are characterized by the following markers: AQP-5+ cells are AEI,
SP-C+ cells are AEII and CC-10+ cells are Clara cells while SP-c+CC-10+ cells are bronchoalveolar stem cells. The gating strategies were as follows: BrdU+ and BrdU- cells were first gated and then the other markers
were detected within the gates. Gating was first done on BrdU+ and BrdU- cells and then individual markers such as TTF-1, Oct3/4, SSEA 3, 4, SCA-1+, Lin-, CD34+ and CD31+ cells were assessed. The percentages,
therefore, do not add up to 100% as only single positive cells are separately assessed in each gate. It is possible that there may be some redundancy but overall, it is possible have a rough idea about the kind of

















has any significance to stem cell niches in the lung is
unknown. Oct3/4+BrdU- cells were decreased by 4.97-
fold post-bleomycin. Therefore, along with the stem cell
population, the mature cells were also probably univer-
sally depleted to be replaced by collagen fiber.
The percentage of SSEA-3, SSEA-4 and Sca-1+ cells
did not differ before and after bleomycin when gated on
BrdU- cells. These markers were expressed on an extre-
mely low number of cells and hence may be of no con-
sequence in this response. Lineage-negative cells showed
a statistically significant 2.8-fold increase. Again this
may indicate that non-hematopoietic cells in the lung
are universally depleted post-bleomycin. Again the per-
centage of this population was so low that this may be
technically ignored. CD34+ hematopoietic progenitors
that were not LRC were also concommitantly increased
14.5-fold post-bleomycin, again corroborating our
hypothesis that there is a recruitment of progenitors of
hematopoietic origin in response to bleomycin. Endothe-
lial progenitors CD31+ cells were also increased 2.9-fold
post-bleomycin. These are the non-stem CD31+ in the
lung. We do not know how this may be significant.
However, again the cell percent was extremely low.
SP-C+ AEII were decreased 3.2-fold and AQP-5+ AEI
were decreased 9.5-fold. This is in keeping with the
overall concept of degeneration of alveolar epithelium in
bleomycin-induced fibrosis. Clara cells were decreased
by 1.3-fold and this was statistically significant. CD45+
and CD45- cells were decreased 3.3-fold and 1.1-fold
post-bleomycin, again in keeping with the overall degen-
eration of lung cell parenchyma in bleomycin-induced
fibrosis.
Short term Hoechst SP experiment
Analysis of inflammatory cells post-bleomycin treatment in
single and double knockout mice
Cellularity of the LP was measured in single cell suspen-
sion by Z1 Beckman particle counter. Only LP post-
bleomycin (day 7) were considered, as our aim was to
look for stem cells in the lung, and the changes in cell
number are more apparent at day 7 than by day 21. The
cell number of BALf and lung did not show any signifi-
cant difference between groups before and after bleomy-
cin treatment, and the histopathologic assessment of the
lung showed conclusive proof of the fibrotic process













































Figure 6 Colony forming units in lung from bromodeoxyuridine-positive cells sorted after 10 weeks of chase. Bromodeoxyuridine single-
positive cells in the lung parenchyma were decreased 4.8-fold post-bleomycin, thus, the putative stem cell population appeared gradually
depleted from lung upon bleomycin treatment. The 0.1 × 106 cells were plated in semi-solid methyl cellulose and CFU were counted after 14
days. All three data points (pink squares) for bleomycin-treated (Bleo) mouse lungs were significantly increased compared to the control (Con)
mouse (blue diamonds). *P < 0.05 was considered statistically significant. Data were pooled from three independent experiments (n = 4 or 5 per
group). Mortality was less than 2%. Averaged data are presented as mean ± SEM of three experiments. Data were collected in duplicate petri
dishes for each sample.
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SP cells isolated from pre- and post-bleomycin treatment
(day 7)
Marker expression by FACS was used when next we
sought to characterize the cells thus sorted (Figure 8),
and was isolated and cultured ex vivo to note the
changes in marker expression over time. Our future
plan with these cells is to differentiate them into lung
lineage-specific cells and monitor their functional effi-
cacy in regenerating lung tissue in bleomycin-induced
fibrosis. For characterization, each mouse group of four
mice lungs were pooled and cell culture was sampled
with detached cell suspension (0.05% trypsin-EDTA) for
FCM. So, day 1 to day 5 refers to the days during which
these cells that were sorted from day 7 post-bleomycin
mouse lungs, were cultured in mouse ES medium. The
samples, each pooled from lungs of four mice (1-4) at 7
days post-bleomycin, will be termed WS 1-4, (WT + sal-
ine), WB 1-4 (WT+bleomycin), NOXS1-4 (gp91phox-/-
+saline), NOXB1-4 (gp91phox-/-+bleomycin), DKOS1-4
(MMP12-gp91phox double knockout+saline), and
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Figure 7 Cellularity in bronchoalveolar lavage fluid and lung before and after bleomycin challenge at day 7 in wildtype vs.
gp91phox-/- and MMP12-gp91phox double knockout mice. Airways were lavaged and cells counted by a Z1 particle counter from Beckman
Coulter. Lung lobes were excised after thorough exsanguination of the mouse by infra-orbital bleeding after ligation of the superior vena cava.
Minced parenchyma was digested with dispase and the resultant cell suspension, filtered of cell debris, was stained with Hoechst dye, and
cellularity assessed. *P < 0.05 compared to control, averaged from three independent experiments. FACsans and flow sorts were done in
triplicate per sample. Samples were counted in duplicate tubes per sample for each data point (n = 4 to 5 per group). Mortality was less than
2%. Abbreviations: WS, saline-treated wildtype mice; WB, wildtype mice treated with bleomycin; NOXS, saline-treated gp91phox null; NOXB,
bleomycin-treated gp91phox null; DKOS, saline treated MMP12- gp91phox double knockout; DKOB, bleomycin-treated MMP12- gp91phox
double knockout.
Banerjee and Henderson Stem Cell Research & Therapy 2012, 3:21
http://stemcellres.com/content/3/3/21
Page 13 of 21
Cells in BALf and lung post-bleomycin over time
The total number of cells and cell subsets was measured
periodically over time in WT and knockout mice (Table
1). The total number of cells was increased in bleomy-
cin-treated NOX-/- mice at day 7 after bleomycin, with
macrophages and lymphocytes contributing most of the
increase. The percentage of Polymorphonuclear neutro-
phils (PMNs) also increased but the total number was
comparable to that in post-bleomycin WT mice. DKO
mice, on the other hand, had a slightly higher total
number of cells than the saline-treated control group,
with lymphocytes and PMNs contributing entirely to the
slight increase. Compared to saline-treated WT mice,
the number of cells increased 6.6-fold one week after
bleomycin treatment. This was denuded at day 14 and
further denuded at day 21. Therefore, similar to pre-
vious data, cell number in BALf was not an indicator of
the extent of fibrosis by day 21. Similar trends were
found in the lung (Table 1C). Day 7 probably signals the
onset of fibrosis by increased cellular recruitment.
Macrophages and T cells are the chief secretors of
TGFb, traditionally thought to activate collagen synth-
esis and deposition by alveolar epithelial cells. Day 8 to
day 21 therefore, is the scar tissue formation period
when AEI and AEII have become denuded. This is
shown in Table 1D (Figure S1 in Additional file 1),
where there is a progressive decrease in AEI through
day 21 while AEII first increased slightly only to equi-
libriate at day 21. The NOX-/- BALf showed a 1.7-fold
increase in cell number, which decreased predictably by
day 21. DKO BALf, however, showed no appreciable
increase over saline-treated mice, either at day 7 or at
day 21. Macrophages seem to be the chief cell popula-
tions accounting for this increase. In lung (Table 1C)
(Figure S2 in Additional file 1) however, on day 7, a
similar trend to that in BALf is found. The only differ-
ence is that both macrophages and lymphocytes make
up for the increase.
Characterization of sorted SP cells in ex vivo culture
Sorted cells from day 7 post-bleomycin mice (Figure 8)
and their corresponding control groups from all three
genotype groups were plated in mouse ES, and FACScan
of surface expression markers was evaluated in culture
every 24 h, before freezing on day 5 of culture. Thus the
data represent the percentage positive for each marker
expression on flow-sorted SP cells in ex vivo culture
with Leukemia Inhibitory Factor (LIF) (Figures 9, 10,
* 
* 
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Figure 8 Percent side population cells in lung before and seven days after bleomycin challenge in wildtype vs. gp91phox-/- and
MMP12-gp91phox double knockout mice. At this point, lung parenchyma was digested by dispase and Hoechst dye effluxing cells (side
population) were isolated. *P < 0.05 compared to control, averaged from three independent experiments. FACsans and flow sorts were done in
triplicate per sample. Abbreviations: WS, saline-treated wildtype mice; WB, wildtype mice treated with bleomycin; NOXS, saline-treated gp91phox
null; NOXB, bleomycin-treated gp91phox null; DKOS, saline treated MMP12- gp91phox double knockout; DKOB, bleomycin-treated MMP12-
gp91phox double knockout.
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11). The total number of cells that could be expanded
was small, to the tune of 104. Most of the cells were
therefore stained and scanned. Cell death was low, as
viability count was taken before staining, and > 90%
cells were alive (data by Trypan blue dye exclusion is
not presented). The stains were again done separately
and scattergrams were collected in un-gated cells and
monostained cells (so they do not add up to 100%)
except for SP-C and CC-10, which were done together,
especially to identify double positive cells, which are
thought to be the putative stem cells.
In the bleomycin-induced fibrosis experiments per-
formed earlier and repeated with this latest batch of
mice, it is apparent that while gp91phox-/- mice
respond with an exaggerated fibrotic manifestation in
lung, MMP12- gp91phox DKO mice show little or no
difference from their saline-treated counterparts. Isola-
tion of SP cells from the lungs of these animals on day
7 post-bleomycin and ex vivo culture for five days may
explain the mechanism for such response on the basis
of changes in their marker expression in culture with
LIF (to not promote differentiation).
Overall, SSEA-3 and 4 remained stationary at quite
high expression throughout the culture period, with
both untreated lung cells from all three genotype groups
as well as bleomycin-treated WT lung cells, except for
the two knockout mice post-bleomycin, where both
were significantly downregulated. Other pluripotent
marker expression was downregulated in all three post-
bleomycin, but of note is the different expression of SP-
Figure 9 Marker expression on wildtype side population cells flow sorted and cultured for five days. Lung parenchyma, homogenized
and digested with dispase, was incubated with Hoechst dye for 90 minutes in a water bath at 37°C. After washing three times with cold PBS,
cells were flow sorted with the FACS ARIA cell sorter from Becton Dickinson. The sorted side population (SP) cells, gated from the typical arch
formed in the scattergram by Hoechst positive cells, were kept in ex vivo culture in ES medium with LIF and assessed for markers by FCM every
day for five days. Percent positive cells for markers on SP cells sorted and cultured in mouse ES medium with LIF. FACsans and flow sorts were
done in triplicate per sample. *P < 0.05 compared to control, averaged from three independent experiments. Abbreviations: WS, wildtype mice
treated with saline; WB, wildtype mice treated with bleomycin; d1-5, days 1 to 5 in culture.
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C-CC-10 double-positive cell population in both saline-
treated and bleomycin-treated knockout cells. The sig-
nificance of this difference is unknown.
Discussion
It is generally important to elucidate airway epithelial
cell lineages and to identify multipotent progenitors as
targets for gene therapy. Stem cells are typically present
in specialized compartments spatially proximal to their
differentiated progeny, but an equivalent paradigm has
not been demonstrated in the airway. We discovered a
distinct population of cells displaying high levels of ker-
atin expression in murine tracheal submucosal gland
ducts, and tested the hypothesis that BrdU LRCs,
thought to represent stem cells, were present in this
compartment. Mice received weekly epithelial damage
by intratracheal detergent or SO2 inhalation for 4 wk
and received intraperitoneal injections of BrdU every 48
h during the injury and repair period. At three and six
days after injury, BrdU-positive epithelial cells were
noted along the entire tracheal length in both basal and
lumenal cell positions. At later time points (20 and 95
days) LRCs were localized to gland ducts in the upper
trachea, and to systematically arrayed foci in the lower
trachea, typically near the cartilage-intercartilage junc-
tion. LRCs were not pulmonary neuroendocrine cells.






















































Figure 10 Marker expression on NOX-/- side population cells flow sorted and cultured for five days. Lung parenchyma, homogenized
and digested with dispase, was incubated with Hoechst dye for 90 minutes in a water bath at 37°C. After washing three times with cold PBS,
cells were flow sorted with the FACS ARIA cell sorter from Becton Dickinson. The sorted side population (SP), cells gated from the typical arch
formed in the scattergram by Hoechst positive cells, were kept in ex vivo culture in ES medium with LIF and assessed for markers by FCM every
day for 5 days. Percent positive cells for markers on SP cells sorted and cultured in mouse ES medium with LIF. FACsans and flow sorts were
done in triplicate per sample. *P < 0.05 compared to control, averaged from three independent experiments. Abbreviations: WS, wildtype mice
treated with saline; WB, wildtype mice treated with bleomycin d7; d1-5, days 1 to 5 in culture; NOXS, saline-treated gp91phox null; NOXB,
bleomycin-treated gp91phox null.
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Heterotopic tracheal grafts after surface epithelial
removal demonstrated reconstitution of a surface-like
epithelium from gland remnants.
On the other hand, SP cells are believed to be derived
from the bone marrow and can be differentiated from
committed tissue stem cells. In models of ablative radia-
tion injury, CD45+ lung SP cells have demonstrated
transient repopulation of the bone marrow and indi-
cated that CD45+ lung SP cells are analogous to the
short-term repopulating hematopoietic cell. In models
of ablative radiation injury, CD45+ SP cells have been
demonstrated to be sufficient for reconstitution of the
bone marrow [15,16]. In addition, in one report, marked
SP cells were shown to repopulate damaged lung [17] in
irradiated mice, resulting in rare, but detectable, fibro-
blasts and alveolar and bronchial epithelial cells. These
findings support the position that tissue SP cells are
hematopoietically derived, pluripotent stem cells that
may play an important role in tissue repair. Other stu-
dies have attempted to address whether SP cells that are
localized to specific tissues maintain their pluripotency.
Distinct populations of tissue-localized SP or Lin-, Sca-1
+ cells that maintain hematopoietic activity have been
identified in muscle [18,19] and liver [18]. Interestingly,
these SP cells have not been identified in PB and are
least frequently found in the bone marrow (0.79% of
nucleated cells) compared with other tissues (0.96 to
15.1% of nucleated cells) [20]. These results suggest that
airway epithelial stem cells are localized to specific
niches [21].
The bleomycin-induced idiopathic pulmonary fibrosis
model in WT and knockout mice was developed in a
Figure 11 Marker expression on DKO SP cells flow sorted and cultured for 5 days. Lungs parenchyma, homogenized and digested with
dispase, was incubated with Hoechst dye for 90 mins in a water bath at 37°C. After washing thrice with cold PBS, cells were flow sorted with
FACS ARIA cell sorter from Becton Dickinson. The sorted Side Population cells gated from the typical arch formed in the scattergram by Hoechst
positive cells were kept in ex vivo culture in ES medium with LIF and assessed for markers by FCM every day for 5 days. Percent positive cells for
markers on SP cells sorted and cultured in mouse ES medium with LIF. FACsans and flow sorts were done in triplicate per sample. *P < 0.05
compared to control, averaged from three independent experiments. Abbreviations: WS, wildtype mice treated with saline; WB, wildtype mice
treated with bleomycin d7; d1-5, days 1 to 5 in culture; DKOS, saline treated MMP12- gp91phox double knockout; DKOB, bleomycin-treated
MMP12- gp91phox double knockout.
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systematic study to investigate whether inflammation
may be involved down- or upstream of the onset of the
fibrotic process as well as to tease out the lung stem cell
niches by inflicting injury to the tissue (Figure 1). In
other words, the degeneration of functional AEI and
AEII and other pulmonary cell types help reveal stem
cell niches by the sheer force of mobilization of putative
progenitors that herald the onset of the regeneration of
lost tissue. Identification of the stem-like characteristics
of the mobilized or homing progenitors’ long term
assays (Figures 4, 5, 6, Table 2) and short term assays
(Figures 7, 8, 9) revealed that post-bleomycin treatment
there was heavy inflammation in the lung parenchyma
as well as the airways (Figures 2, 3, Table 1). The pre-
sence of a large number of myeloid inflammatory cells
recruited to the airways and obtained in the exudates,
shows this inflammation to be mainly Th1-driven.
As communicated in our publication [22], both
inflammation and airway hyperreactivity were more
extensive post-OVA in NOX or gp91phox knockout
mice than in WT mice. Although OVA-specific IgE in
plasma were comparable in WT and knockout mice,
enhanced inflammatory cell recruitment from circula-
tion and cytokine release in lung and BALf, accompa-
nied by higher airway resistance, as well as enhanced
pause in response to methacholine, indicate a regulatory
role for nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase in the development of allergic
asthma. Also, while T cell-mediated functions like Th2
cytokine secretion, and proliferation to OVA were upre-
gulated synchronous with the overall robustness of the
asthma phenotype, macrophage upregulation in func-
tions such as proliferation, mixed lymphocyte reaction,
and MCP-1-directed chemotaxis, but downregulation of
respiratory burst response, indicate a forking in their
signaling pathways. The gp91phox-/- MMP12 DKO mice
show a similar phenotype to the gp91phox-/-, showing
the non-involvement or synergistic involvement of
MMP12 in the response pathway. Contrary to a Th2-
driven inflammation as in this OVA-induced allergic
asthma model, bleomycin-induced IPF.Idiopathic Pul-
monary Fibrosis (IPF) obviously takes a different afferent
immune response pathway to develop. However, the
most striking finding is with the fibrosis model, where
there is no inflammation in the DKO mice, as well as
no fibrosis, indicating that inflammation is a prerequisite
to fibrosis.
The BrdU+CD45+ population comprises hematopoietic
cells with pluripotent properties. Post-bleomycin they
are increased 0.7 fold, again corroborating our theory
that progenitors from circulation form a component of
the lung stem cell scenario. Most BrdU+ cells were
CD45- cells (non-hematopoietic origin). There was no
significant alteration in their number when assessed by
gating on CD45- alone. SP-C+CC-10+ cells are the
broncho-alveolar stem cells (BASCs). Gated BrdU+ cells
show a 38.9-fold decrease in this population, which
formed the majority of the BrdU+ cells before, and con-
stituted a bare 2% post-bleomycin in the mouse lung.
This is perhaps the most important finding of the pulse
chase study, that BASCs are so drastically mobilized and
depleted after 10 weeks of bleomycin-induced fibrosis.
VEGF is a growth factor traditionally associated with
increased vascularization. Since fibrosis is a degenerative
disease, we measured VEGF+ cells in the BrdU+ popula-
tion and found that there was a 1.8-fold decrease post-
bleomycin. If VEGF is assumed to be a pro-fibrotic sig-
nal, then decrease in VEGF+ LRC may indicate either
that the fibrotic process is slowing wearing off, or VEGF
is assumed to be a signal for progenitor mobilization. Of
significance is that there is no change in the BrdU-
BASC population. Does this mean that there is a very
small quiescent population of these cells, even though
the there is a BrdU+ BASc, which is otherwise respon-
sive to a bleomycin challenge? VEGF+ cells were
increased 4.6-fold post -bleomycin. Interestingly, while
the VEGF+ LRC were decreased, VEGF+ BrdU- cells
were increased post-bleomycin. This may help counter-
balance the mobilization of VEGF+ cells from stem cell
niche (Table 2A) (Figure S3 in Additional file 1). There
was no significant difference in the colony-forming
potential of BrdU- cells before and after bleomycin after
the 10 week chase.
SP cells were flow-sorted from lungs of mice at seven
days post-bleomycin exposure. This was done primarily
on the assumption that the fibrosis process was just
beginning. However, as apparent from cell traffic data in
the airways (Table 1A-C), especially the real-time trend
on days 7, 14 and 21, speak of a primary inflammatory
recruitment followed by an exodus out of the lung that
is slowly replaced by fibrosis. This was significant. SP
cells from day 7, therefore, are the progenitors that are
mobilized coinciding with the inflammatory cell mobili-
zation from circulation. It may be that inflammatory
cells produce signals to induce mobilization of lung
stem cells from tissue niche or they may bring with
them progenitors mobilized from the bone marrow.
Whatever the origin, lineage commitment may be
occurring when the same cells cultured in vitro show
up- or downregulation of different markers.
Fibrosis induced by bleomycin was a deliberate injury
given to the lung tissue to tease out progenitors residing
within the tissue for exigencies. In the process, the
study aimed to identify, isolate and characterize stem
cells of the adult lung. Hence we used the bleomycin-
induced pulmonary fibrosis model. It is true that multi-
ple progenitors exist in the lung, as the reviewer has
suggested. However, the scope of the present study was
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simply to characterize the cells with stem-like properties
rather than enumerate all the different kinds that exist
there, the ramification of which is beyond the scope of
this study. We have addressed colony-forming units in
the injured vs. healthy lung and shown that both LRC
and SP increase, and we additionally identified CD34+
and CD31+, putative hematopoietic and endothelial pro-
genitors within the tissue (Table 2).
Fibrosis sets in when functional epithelial, muscular
and endothelial cells making up the structural architec-
ture of the lung are progressively degenerated and
replaced by extra cellular matrix protein (ECM). The
injury axis of SDF-1a-CXCR4 typically regulates mobili-
zation and homing of pluripotent or limited lineage-
committed hematopoietic and non-hematopoietic cells
from bone marrow, peripheral circulation, secondary
lymphoid tissue and lung tissue itself, to try to replenish
damaged tissue and reverse fibrosis. The perturberance
of normal physiological homeostasis of the lung recalls
cells to replace dead or damaged cells, mostly AEII in
the lung [22].
At the beginning of their life outside the lungs (Fig-
ures 9, 10, 11), the numbers of sorted SP cells expres-
sing mature cell markers were very low but as the
culture progressed in the presence of LIF (under nega-
tive selection pressure where differentiation is inhibited)
markers of stem-like characteristics were downregulated,
indicating that despite the presence of LIF, a slow
maturation process has begun. Of note is the expression
of the Oct3/4 pluripotent marker, which was about 16%
(P < 0.05) lower than in the NOX compared to saline-
treated WT as well as saline-treated DKO mice. This
unexpected down-modulation may account for the unre-
gulated development of fibrosis in the single knockout
(gp91phox-/-) mouse only, as opposed to the DKO
mouse, which is protected. Whether the MMP12 dele-
tion in addition to the NADPH oxidase sub-unit dele-
tion has a counteractive and therefore protective effect
towards development of fibrosis is speculative as it is
beyond the scope of this paper, and needs more work
with the Wnt/b catenin pathway to reveal molecular
mechanisms underlying this protection.
On the other hand, cellular senescence has been
shown to be a state of irreversible growth arrest [23],
characterized by distinct morphological and biochemical
changes and induced either by telomere shortening or
by telomere-independent signals such as DNA damage
and oxidative stress; using AEII DNA-damaging agents,
such as bleomycin, induced a senescence phenotype.
Regeneration of the injured epithelium, which involves
proliferation of AEII cells, was seriously affected, result-
ing in the absence of appropriate re-epithelialisation.
This pathway of impaired epithelial cell regeneration,
leading to pulmonary fibrosis, suggests that proliferation
of AEII is important for preventing the progress of bleo-
mycin-induced pulmonary fibrosis. The senescent cells
produced higher levels of matrix metalloproteinases,
such as collagenases and stromelysin, and of profibrotic
cytokines, such as interleukin (IL)-1b and TGF-b, and
indicates that senescent cells may be involved not only
in impaired tissue regeneration, but also in the inflam-
matory response and extracellular matrix remodelling.
The extent of decrease in its expression in the bleo-
mycin-treated cells was also 2-fold greater in the
gp91phox-/- compared to WT and DKO mice-derived
cells. The other interesting modulation in marker
expression is that of the double-positive BASC cells (SP-
C+CC-10+) that was sharply downregulated by day 2 of
culture in the WT, but showed a much more gradual
downregulation in the gp91phox-/- (d4) mice. The DKO
mice on the other hand was 2-fold lower than the first
two, in both the saline- and the bleomycin-treated mice,
while the percentage of these BASC in the WT and
gp91phox-/- mice decreased almost to nil (since this is
an ex vivo culture excluding cell turnover per se, we
may assume that the markers themselves downregulate).
In the absence of more detailed study, we may simply
comment that the rate and degree of BASC may have a
developmental significance in the progression of fibrosis.
Mesenchymal cells, as well the stroma of the lungs, may
have a significant role to play in the future development
of the cells [24-26].
As a commentary and hypothesis, we offer the follow-
ing views: the cells within a tissue such as the lung,
where rapid turnover of cells is the rule where efficient
regeneration is needed to balance the high level of oxi-
dative wear and tear, in the light of the data presented
in this paper, we believe that the identity of a cell, both
structural and functional, undergoes a dynamic plasticity
by which it can change back and forth between func-
tionally competent lineage-restricted cells of the differ-
ent anatomical tissue sub-types of the lung and
progenitor-like cells that can differentiate and trans-dif-
ferentiate into cells of the required type, according to
the current demand to restore homeostatsis in the lung
[27]. To accomplish this there must be efficient and
seamless de-differentiation and differentiation of the
same cellular pool by simply switching certain defined
molecular switches on and off. The data showing the
dynamics of marker expression in the lung and airways
of an injured lung in real time testify to this. The so-
called niches therefore may be both anatomical, occupy-
ing distinct regions of the lung, as well as functional,
that is irrespective of their spatial distribution, cells can
undergo rapid changes as to their developmental iden-
tity according to the exigent situation born out of a par-
ticular injury [26]. Studies [28-31] describe how cells
fished out from adult tissue using similar strategies, and
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suitably engineered, can be an unlimited source of cells
to counter the process of degeneration. The above study
provides valuable insight into this translational aim.
Conclusion
In summary, interpreting data presented in this commu-
nication, the following conclusions may be drawn:
Firstly, the long term BrdU pulse chase experiments
infer that (1) the increase in the hematopoietic progeni-
tor pool in the lung indicated that exogenous progeni-
tors from the circulation contribute to lung
regeneration; (2) most non-stem cells (possibly accessory
cells) were non-hematopoietic in origin indicating that
despite tissue turnover and some spontaneous resolution
of fibrosis as reported, BASCs are drastically depleted,
possibly necessitating recruitment of progenitors from
the hematopoietic pool; (3) loss of VEGF+ LRC may
indicate either a gradual resolution of the fibrosis pro-
cess or a signal for progenitor mobilization from niches;
(4) the BrdU- BASC population may be a small quies-
cent population that remains as a reserve for more
severe lung injury; (5) increase in VEGF+ non-LRC may
indicate a checkpoint to counterbalance the mobilization
of VEGF+ cells from the stem cell niche and a protective
measure against complete depletion of the same. Sec-
ondly, from the short term SP population analysis stu-
dies, the following conclusions can be drawn: (1)
inflammation is a prerequisite for fibrosis; (2) SP cells,
being the putative stem cells in the lungs, were
increased (either by self renewal or by recruitment from
the exogenous bone marrow pool) post-bleomycin in
NOX-/- but not in DKO mice, indicating the necessity
of cross-talk between gp91phox and MMP-12 in this
process; (3) ex vivo cultured SP progressively lose pluri-
potent markers, notably BASC (SPC+CC10+) - the sig-
nificance of this is unknown.
Stem/progenitor cells can be used to repair defects in
the airway wall, resulting for example, from tumors,
trauma, tissue reactions following long-time intubations,
or diseases that are associated with epithelial damage.
Several potential sources of cells for airway epithelium
have been identified. These can be divided into two
groups. The first group consists of endogenous progeni-
tor cells present in the respiratory tract. This group can
be subdivided according to location into (a) a ductal cell
type in the submucosal glands of the proximal trachea;
(b) basal cells in the intercartilaginous zones of the
lower trachea and bronchi; (c) variant Clara cells (Clara
v-cells) in the bronchioles; (d) variant Clara cells at the
junctions between the bronchioles and the alveolar
ducts and (e) alveolar type II cells. This classification of
progenitor cell niches is controversial. The second
group consists of exogenous stem cells derived from
other tissues in the body. This second group can be
subdivided into: (a) embryonic stem (ES) cells, induced
pluripotent stem (iPS) cells, or amniotic fluid stem cells;
(b) SP cells from bone marrow or epithelial stem cells
present in bone marrow or circulation and (c) fat-
derived mesenchymal cells. Airway epithelial cells can
be co-cultured in a system that includes a basal lamina
equivalent, extracellular factors from mesenchymal
fibroblasts, and in an air-liquid interface system.
Recently, spheroid-based culture systems have been
developed. Several clinical applications have been sug-
gested: cystic fibrosis, acute respiratory distress syn-
drome, chronic obstructive lung disease, pulmonary
fibrosis, pulmonary edema, and pulmonary hypertension.
Clinical applications so far are few, but include subglot-
tic stenosis, tracheomalacia, bronchiomalacia, and
emphysema [32-35].
Additional material
Additional file 1: Figure S1 Scattergrams of CD45- cells with
alveolar epithelial specific markers scanned by FACS from LP of
mice from different genetic groups before and after bleomycin
treatment (data presented in Table 1D). CD45- cells were gated. Left
panel, SP-C+ AEII cells; right panel, AQP-5+ AEI; AEII are WS 5.4%, WB
7.2%, NOXS 4.5%, NOXB 5.8%, DKOS 5.6%, DKOB 6.2%; AEI are: WS 93.9%,
WB 60.4%, NOXS 94%, NOXB %, DKOS 90%, DKOB 92.3% in this
representative scattergram of one of the three independent experiments
which were averaged and presented as mean ± SEM. Figure S2
Scattergrams of CD45+ hematopoietic cells scanned by FACS from lung
parenchyma of mice from different genetic groups before and after
bleomycin treatment (data presented in Table 1C). Lung parechyma (day
7). Panel 1 A-C, myeloid cells: cells are CD45+ gated and macrophages
and neutrophils. GR-1+hiF4/80+lo cells are neutrophils and GR-1+loF4/80
+hi cells are macrophages. In knockout mice, post-bleomycin lung
parenchyma show a greater presence of macrophages than neutrophils,
showing that these were mobilized from local niches (GR-1+lo). A,
Macrophage (Mf)36.7%, neutrophil (PMN) 14.8%; B, Mf 56.8%, PMN 1.8%
and C, Mf 59.8%, PMN 2.3%, Panel 2D-E, lymphoid cells: D, T cells; E, B
cells. Figure S3. Scattergram of Brd+ cells also individually expressing
different pluripotent and pulmonary lineage specific markers (data
presented in Table 2A). Wildtype mouse cells were treated with BrdU
and counterstained with SP-C. The upper right (UR) quadrant shows
double-positive BrdU+SP-C+ cells.
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